['nonalcoholic steatohepatitis']
['jkb-121: 5 mg twice daily', 'jkb-121: 10 mg twice daily', 'placebo']

        Inclusion Criteria:

          1. Age ≥ 18 years

          2. Provision of written informed consent

          3. Biopsy-proven NASH within 12 months or at screening

          4. ALT > 40 U/L for women and > 60 U/L for men at screening and at least once in the
             previous 12 months.

          5. HBA1C of ≤ 9.0

        Exclusion Criteria:

          1. Any chronic liver disease other than NASH

          2. Cirrhosis, as assessed clinically or histologically

          3. Presence of vascular liver disease

          4. BMI ≤ 25 kg/m2

          5. Excessive alcohol use (> 20 g/day) within the past 2 years

          6. AST or ALT > 250 U/L.

          7. Type 1 diabetes mellitus

          8. Bariatric surgery in the past 5 years.

          9. Weight gain of > 5% in past 6 months or > 10% change in past 12 months.

         10. Contraindication to MRI

         11. Inadequate venous access

         12. HIV antibody positive, hepatitis B surface antigen positive (HBsAg), or Hepatitis C
             virus (HCV) RNA positive.

         13. Receiving an elemental diet or parenteral nutrition

         14. Chronic pancreatitis or pancreatic insufficiency

         15. Any history of complications of cirrhosis

         16. Concurrent conditions:

               -  Inflammatory bowel disease

               -  Significant cardiac disease

               -  chronic infection or immune mediated disease

               -  Any malignant disease

               -  Prior solid organ transplant

               -  Any other concurrent condition which, in the opinion of the investigator, could
                  impact adversely on the subject participating or the interpretation of the study
                  data.

         17. Concurrent medications which may treat NASH

         18. HbA1C > 9.0%

         19. Pregnancy or breastfeeding.
      